BiotechTube

ATR04-484 + Vehicle

Phase 1/2Recruiting
0 watching 0 views this week💤 Quiet
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

EGFR Inhibitor-associated Rash

Conditions

EGFR Inhibitor-associated Rash

Trial Timeline

Aug 25, 2025 → Feb 15, 2027

NCT ID
NCT06830863

About ATR04-484 + Vehicle

ATR04-484 + Vehicle is a phase 1/2 stage product being developed by Azitra for EGFR Inhibitor-associated Rash. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06830863. Target conditions include EGFR Inhibitor-associated Rash.

Hype Score Breakdown

Clinical
13
Activity
8
Company
2
Novelty
4
Community
3

Clinical Trials (1)

NCT IDPhaseStatus
NCT06830863Phase 1/2Recruiting

Competing Products

20 competing products in EGFR Inhibitor-associated Rash

See all competitors
ProductCompanyStageHype Score
YH25448YuhanPhase 1/2
41
YH32364YuhanPhase 1/2
41
Datopotamab deruxtecanDaiichi SankyoPre-clinical
23
HER3-DXdDaiichi SankyoPre-clinical
23
ASP8273Astellas PharmaPhase 2
52
radio-labeled naquotinib + naquotinibAstellas PharmaPhase 1
33
erlotinibAstellas PharmaPhase 1
33
ASP8273 Capsules + ASP8273 Capsules AAstellas PharmaPhase 2
52
famitinib po + HS-10296 poJiangsu Hengrui MedicinePhase 2
52
ABT-414AbbViePre-clinical
23
AZD9291 40 mg + AZD9291 80 mgAstraZenecaPhase 1
33
Osimertinib-based adaptive treatment + Osimertinib 80 MGAstraZenecaPhase 2
52
AZD9291 + MEDI4736AstraZenecaPhase 3
77
EGFR TKIs (gefitinib, erlotinib, afatinib, et al)AstraZenecaPre-clinical
23
AZD9291AstraZenecaPre-clinical
23
OsimertinibAstraZenecaPhase 2
52
Dasatinib + OsimertinibAstraZenecaPhase 1/2
41
AZD9291 80mg oral each dayAstraZenecaPhase 3
77
Tremelimumab + DurvalumabAstraZenecaPhase 2
52
OsimertinibAstraZenecaPhase 2
52

Other Products from Azitra

ATR-04Phase 1/2
33
ATR12-351Phase 1
25